Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions

ISSN Print: 2157-9423
ISSN Online: 2157-9431
www.scirp.org/journal/pp
E-mail: pp@scirp.org

"Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions"
written by Jan M. Kitzen, Joseph V. Pergolizzi Jr., Robert Taylor Jr., Robert B. Raffa,
published by Pharmacology & Pharmacy, Vol.9 No.9, 2018

has been cited by the following article(s):

[1]	Development of apremilast nanoemulsion-loaded chitosan gels: In vitro evaluations and anti-inflammatory and wound healing studies on a rat model
	Gels, 2022

[2]	Influence of heat processing on the anti-inflammatory activity of fresh Smilax glabra based on PDE4 inhibition
	Food Chemistry: X, 2022

[3]	Anti-inflammatory activity of non-selective PDE inhibitor aminophylline on the lung tissue and respiratory parameters in animal model of ARDS
	2022

[4]	Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma.
	2020

[5]	Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials
	2020

[6]	Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems
	2020

[7]	Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma
	2020

[1]	Anti-inflammatory activity of non-selective PDE inhibitor aminophylline on the lung tissue and respiratory parameters in animal model of ARDS Journal of Inflammation, 2023 DOI:10.1186/s12950-023-00337-y

[2]	Development of Apremilast Nanoemulsion-Loaded Chitosan Gels: In Vitro Evaluations and Anti-Inflammatory and Wound Healing Studies on a Rat Model Gels, 2022 DOI:10.3390/gels8050253

[3]	Influence of heat processing on the anti-inflammatory activity of fresh Smilax glabra based on PDE4 inhibition Food Chemistry: X, 2022 DOI:10.1016/j.fochx.2022.100425

[4]	Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials Clinical Drug Investigation, 2020 DOI:10.1007/s40261-020-00905-7

[5]	Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia, 2020 DOI:10.1016/j.clml.2020.03.016

[6]	Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems Drug Discovery Today, 2020 DOI:10.1016/j.drudis.2020.09.023